-

Bristol-Myers Squibb Postpones April 2, 2020 Investor Day

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced that due to the ongoing COVID-19 pandemic, it will reschedule its planned April 2, 2020 Investor Day for a later date. The company will continue to assess the situation and follow guidance from local and global health authorities to determine the new date.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

Contacts

Bristol-Myers Squibb
Media:
media@bms.com
609-252-3345

Investors:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, ngoworek@bms.com

Bristol-Myers Squibb Company

NYSE:BMY

Release Summary
Bristol-Myers Squibb Postpones April 2, 2020 Investor Day
Release Versions
$Cashtags

Contacts

Bristol-Myers Squibb
Media:
media@bms.com
609-252-3345

Investors:
Tim Power, 609-252-7509, timothy.power@bms.com
Nina Goworek, 908-673-9711, ngoworek@bms.com

More News From Bristol-Myers Squibb Company

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma

PRINCETON, N.J.--(BUSINESS WIRE)--US FDA Grants Priority Review to Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Chemotherapy Combination for Classic Hodgkin Lymphoma...

Bristol Myers Squibb Announces Dividend Increase

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Dividend Increase...

Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025...
Back to Newsroom